Back to search results

TLN-121 for Relapsed or Refractory Non-Hodgkin Lymphomas

This study is testing the safety and initial effectiveness of a drug called TLN-121, by itself and with another drug called TLN-254. It's for people with non-Hodgkin lymphomas that have come back or haven't responded to at least two previous treatments, specifically diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) grade 3b, or transformed follicular lymphoma. The main goal is to see how many participants experience side effects and how severe they are over two years. This study is also looking at how the body handles the drugs and if they show any early signs of shrinking tumors. The drugs work by targeting CAR T cells. The study aims to enroll 180 participants.

Study design
This interventional study plans to enroll 180 participants. The specific phase of the study is not mentioned.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to two years to monitor for side effects and other safety measures.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07082803

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Recruiting
PHASE1Ages 18+InterventionalTreatment
Treeline Biosciences, Inc.
~180 participants
Updated 2026-07-20 on ClinicalTrials.gov
What's tested:TLN-121TLN-254

At a glance

Recruiting sites
14 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants experiencing adverse events (AEs) that meet protocol-defined dose-limiting toxicity (DLT) criteria following administration of TLN-121 alone or in combination with TLN-254.
Measured over Up to 2 years
+3 more outcomes measured

Conditions

Lymphoma
Lymphoma, Non Hodgkin

Explore related trials

Diffuse Large B-Cell LymphomaFollicular LymphomaHigh Grade B-Cell LymphomaMature T-Cell and NK-Cell Non-Hodgkin LymphomaNon-Hodgkin Lymphoma

Where it's being run

14 sites across 12 states
New York2
Victoria2
California1
Michigan1
Missouri1
Pennsylvania1
Tennessee1
Texas1

Who to contact

Treeline Clinical Operations
[email protected]
857-228-0050
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Nodal T-follicular helper (Tfh) cell lymphoma angioimmunoblastic; Follicular helper T-cell lymphoma, angioimmunoblastic type (AITL).
Nodal Tfh cell lymphoma, follicular type; Follicular helper T-cell lymphoma, follicular type.
Nodal Tfh cell lymphoma, NOS; Follicular helper T-cell lymphoma, NOS. 3. High-Grade B-Cell Lymphoma that has relapsed after, or not responded to at least 2 prior systemic treatment regimens. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

What this trial measures

  • Number of participants experiencing adverse events (AEs) that meet protocol-defined dose-limiting toxicity (DLT) criteria following administration of TLN-121 alone or in combination with TLN-254.Up to 2 years
  • Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs)Up to 2 years
  • Clinically significant ECG QT Interval from baseline in safety laboratory test results, assessed as per NCI CTCAE v5.0Up to 2 years
  • Clinically significant laboratory abnormalities from baseline in safety laboratory test results, assessed as per NCI CTCAE v5.0Up to 2 years